Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional ...

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough ...

Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease ...

US-based biopharmaceutical company Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary fibrosis (IPF). The double-blind, ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

Researchers led by Virginia Tech have found that inhibiting proteins ID1 and ID3 can halt and even reverse lung scarring in pre-clinical models of idiopathic pulmonary fibrosis. The approach improved ...

LTI-03 is designed to protect and restore the function of the oxygen uptake cells and control lung fibrosis. Credit: SewCreamStudio / Shutterstock. US-based biopharmaceutical company Rein Therapeutics ...